|
1. |
Impressum, Vol. 13, No. 4, 1990 |
|
Onkologie,
Volume 13,
Issue 4,
1990,
Page 233-233
Preview
|
PDF (407KB)
|
|
ISSN:0378-584X
DOI:10.1159/000216768
出版商:S. Karger GmbH
年代:1990
数据来源: Karger
|
2. |
Inhalt, Vol. 13, No. 4, 1990 |
|
Onkologie,
Volume 13,
Issue 4,
1990,
Page 234-234
Preview
|
PDF (566KB)
|
|
ISSN:0378-584X
DOI:10.1159/000216769
出版商:S. Karger GmbH
年代:1990
数据来源: Karger
|
3. |
Therapeutic Aspects of Low-Risk Breast Cancer |
|
Onkologie,
Volume 13,
Issue 4,
1990,
Page 237-243
K. Höffken,
Preview
|
PDF (3667KB)
|
|
摘要:
Attempts to treat patients suffering from metastasizing or primary operable breast cancer in a risk adapted fashion have always been dependant on the detection and clinically relevant ranking of prognostic parameters. Despite a variety of assumed prognostic parameters and description of prognostic indices no generally accepted definition of low or high risk breast cancer has been established as yet. Nevertheless, attempts have been successful to accomplish risk adapted treatment strategies that resulted in a substantial reduction in treatment related morbidity. Thus, replacement of surgical ablation procedures by drugs manipulating hormonal feedback regulation has yielded less side effects. Furthermore, new antiestrogens and antigestagens are aiming at a reduction in the rate and degree of toxicity. In addition, chemotherapy of metastasizing disease as well as adjuvant systemic therapy is being investigated with consideration of the concept of a maximum in efficacy and a minimum in toxicity.
ISSN:0378-584X
DOI:10.1159/000216770
出版商:S. Karger GmbH
年代:1990
数据来源: Karger
|
4. |
Ether Lipids and Derivatives as Investigational Anticancer Drugs |
|
Onkologie,
Volume 13,
Issue 4,
1990,
Page 245-250
W.E. Berdel,
Preview
|
PDF (3324KB)
|
|
摘要:
There is considerable evidence that certain ether lipids represent a new class of antineoplastic agents. The activity of some of these structures is partially mediated through nonspecific host resistance cells. In addition, more importantly, these ether lipids have been shown to be cytotoxic for cells from a wide variety of tumors and leukemias. The site of the cytotoxic action of ether lipids appears to be the cell membrane. They inhibit the biosynthesis of phosphatidylcholine as well as the activity of protein kinase C and might interfere with some growth factor receptors. Higher concentrations of some of these compounds are not compatible with the lipid bilayer matrix of the membrane. However, it remains uncertain whether or not these effects represent the only mechanisms for the cytotoxic action of this material. Further experiments elucidating the molecular mechanisms in the cytotoxicity of these compounds are necessary. In vivo a wide variety of mouse and rat tumors have been found to be sensitive to the therapeutic activity of ether lipids, with other tumor and leukemia models, however, being resistant to this material. Clinical phase I pilot trials have been completed, showing tumor response in a small number of patients treated, and 3 drugs are currently in phase II studies. Some of these ether lipids are preferentially cytotoxic to leukemic cells in comparison with normal bone marrow cells within a certain dose range. Thus, they are suitable for purging residual leukemic cells from remission bone marrow used for autologous bone marrow transplantation. A phase I/II study of autologous bone marrow transplantation in acute leukemia using bone marrow cells treated with ether lipids is in progress.
ISSN:0378-584X
DOI:10.1159/000216771
出版商:S. Karger GmbH
年代:1990
数据来源: Karger
|
5. |
Role of Thoracic Radiotherapy Combined with Chemotherapy in Limited Stage Small Cell Lung Cancer (SCLC) |
|
Onkologie,
Volume 13,
Issue 4,
1990,
Page 253-258
A. Kraft,
H. Arnold,
T. Zwingers,
H. Bodemann,
F.v. Bültzingslöwen,
W. Hinkelbein,
M. Wannenmacher,
Preview
|
PDF (2592KB)
|
|
摘要:
We initiated a prospective randomized multicenter trial to clarify the role of radiotherapy in the treatment of the primary tumor in small cell lung cancer stage limited disease. Patients were randomized to receive only chemotherapy (n = 27), or chemotherapy and radiotherapy of 30 Gy (n = 34) or chemotherapy and radiotherapy of 50 Gy (n = 30). Radiotherapy was administered after the third chemotherapy cycle. All patients received prophylactic totalbrain irradiation of 30 Gy. The chemotherapy consisted of 6 cycles of adriamycin, cyclophosphamide and vincristin (ACO). 415 patients entered the trial. According to eligibility criteria 97 patients were randomized and 91 patients were eval·uable for response. The total response rate (CR and PR) was 69% not being statistically different between all groups. No differences in survival time were observed between patients receiving 30 Gy (median = 13.5 months) and those receiving 50 Gy (median = 12.4 months). However patients treated with radiotherapy and chemotherapy showed a statistically significant improvement of survival time compared to patients receiving chemotherapy alone (median = 9.7 months)
ISSN:0378-584X
DOI:10.1159/000216772
出版商:S. Karger GmbH
年代:1990
数据来源: Karger
|
6. |
Die postoperative adjuvante Ganzabdomenbestrahlung beim Ovarialkarzinom |
|
Onkologie,
Volume 13,
Issue 4,
1990,
Page 260-267
H. Lindner,
N. Willich,
A. Atzinger,
G. Schubert-Fritschle,
Preview
|
PDF (3671KB)
|
|
摘要:
79 Patientinnen mit Ovarialkarzinom der Stadien I–III erhielten nach unterschiedlich radikaler Operation als alleinige adjuvante Maßnahme eine Ganzabdomenbestrahlung in moving-strip- oder open-field-Technik mit einer mittleren Dosis von 22,5 Gy und eine Aufsättigungsbestrahlung des Beckens bis zu einer mittleren Dosis von 45,0 Gy. Bei einer medianen Beobachtungsdauer von 57 Monaten beträgt die 5-Jahresüberlebensrate des Gesamtkollektivs 66 ± 6 % die 5-Jahresre-zidivfreiheitsrate 63 ± 6 %. Es zeigt sich keine eindeutige Abhängigkeit der Überlebensraten von der Operationsradikalität, der Histologie und dem Malignitätsgrad, dagegen eine statistisch signifikante Abhängigkeit vom Stadium, vom Vorhandensein eines makroskopischen Tumorrests, vor allem aber von den Risikogruppen nach Dembo. 5-Jahresüberlebensrate bei intermediaterisk: 78 ± 7%, bei high-risk: 22 ± 11%. Bei weitgehendem Fehlen von entsprechenden randomisierten Studien stellt die postoperative Ganzabdomenbestrahlung bei intermediate-risk-Patientinnen eine Behandlungsmethode mit reproduzierbaren günstigen Resultaten dar, die aufgrund der vergleichsweise geringen Toxizität anderen Adjuvanstherapien gegenüber derzeit mindesten
ISSN:0378-584X
DOI:10.1159/000216773
出版商:S. Karger GmbH
年代:1990
数据来源: Karger
|
7. |
Vaginosonographie als Screeningmethode zur Erkennung von Adnextumoren in der Postmenopause? |
|
Onkologie,
Volume 13,
Issue 4,
1990,
Page 268-270
R. Osmers,
M. Völksen,
W. Rath,
W. Kuhn,
Preview
|
PDF (1332KB)
|
|
摘要:
Bei 212 postmenopausalen, nicht hormonsubstituierten Frauen wurden insgesamt 424 Adnexregionen vaginosonographisch untersucht. 155 Patientinnen waren beschwerdefrei, bei 57 Patientinnen lag eine Postmenopausenblutung vor. Ein pathologischer Befund wurde für 48 Adnexregionen erhoben (11,3%). Darunter befanden sich 2 Ovarialkarzinome. Beide Fälle waren klinisch inapparent. Insgesamt erwies sich die Vaginosonographie als einfache und effektive Methode zur Erfassung von Adnextumoren postmenopausaler Fraue
ISSN:0378-584X
DOI:10.1159/000216774
出版商:S. Karger GmbH
年代:1990
数据来源: Karger
|
8. |
High-Dose Epirubicin in Combination with Cyclophosphamide (HD-EC) in Advanced Breast Cancer: Final Results of a Dose Finding Study and Phase II Trial |
|
Onkologie,
Volume 13,
Issue 4,
1990,
Page 272-278
N. Marschner,
G.A. Nagel,
J.-H. Beyer,
M. Adler,
A. Ammon,
Preview
|
PDF (3093KB)
|
|
摘要:
In der Dosisfindungsstudie konnte gezeigt werden, daß eine Steigerung der Epirubicindosis in den Dosisbereich von 120 mg/m2 in Kombination mit Cyclophosphamid (600 mg/m2) möglich ist. Die Phase II-Studie überprüfte die Effektivität und Toxizität der Chemotherapie-kombination Epirubicin (120 mg/m2) und Cyclophosphamid (600 mg/ m2) bei 3wöchentlicher Applikation. In die Phase Il-Studie wurden 34 Patientinnen mit metastasiertem Mammacarcinom aufgenommen. Alle Patientinnen hatten zum Studienbeginn noch keine palliative chemotherapeutische Behandlung erhalten. Von der Studie wurden Patientinnen mit Knochen- oder Gehirnmetastasen und Patientinnen mit einem erhöhten Risiko für den Anthrazyklineinsatz ausgeschlossen. Die Ergebnisse der High-dose Epirubicin-Therapie lassen sich gut mit den besten aus der Literatur bekannten Daten für die Behandlung des metastasierten Mammacarcinoms vergleichen. Gesamtremissions-rate 73% (35% CR, 38% PR), mediane Zeit bis zur Progression 58 Wochen für CR (32–168) und 52 Wochen für PR (24–110); mediane Überlebenszeit für CR 71 + Wochen (52–196 +), für PR 74 + Wochen (40–134+). Nach Feststellung einer stabilen Remission wurde die Chemotherapie beendet, eine Erhaltungstherapie wurde nicht verabreicht. Dies führte zu einem sehr günstigen Verhältnis der Therapiezeit zum sich anschließenden Zeitraum ohne Chemotherapie. Das Verhältnis lag bei 10/62 Wochen für die CR-Gruppe und bei 12/49 Wochen für die PR-Gruppe. Der Therapieerfolg zeigte sich bei 80% der späteren Patientinnen mit CR oder PR bereits nach dem 1. Zyklus. Das sehr frühzeitige Einsetzen der Remission und die kurzzeitige Chemotherapiedauer bis zum Erreichen des besten Ansprechens waren die größten Vorteile
ISSN:0378-584X
DOI:10.1159/000216775
出版商:S. Karger GmbH
年代:1990
数据来源: Karger
|
9. |
Results and Prognosis of Acute Non-Lymphocytic Leukemia in Adults |
|
Onkologie,
Volume 13,
Issue 4,
1990,
Page 280-284
H.D. Kleine,
A. Birnbach,
G. Exeriede,
H. Link,
H. Poliwoda,
M. Freund,
Preview
|
PDF (2143KB)
|
|
摘要:
Between 1977–87, 319 patients with AML were admitted to Hannover Medical School. At all 41 of these patients were not treated (median duration of survival 0.6 months). Among the 278 treated patients, there was a CR rate of 53.6% the median duration of remission was 10.1 months and the median duration of survival 7.0 months. The patients with FAB-classification M4-M5 had a worse prognosis than those with M1-M3. Patients under 50 years of age had a significant higher remission rate and survival time than those over 50 years. In the last 10 years, the remission rate rase from 37.3% to 61.0% (p = 0.1776). There was a rise in median duration of survival from 5.9 months (1977–79) to 8.0 months (1984–85) (p < O.001). The median remission time decreased from 15.8 months (1977–79) to 12.0 months (1984–85) (p < O.001). After the first reinduction therapy, the remission rate (46.6%), duration of remission (5.3 months), and duration of survival (4.1 months) was lower than after primary therapy. After the second reinduction therapy the CR rate was 69.2%, and the remission time 2.9 months. The CR rate after the third reinduction therapy
ISSN:0378-584X
DOI:10.1159/000216776
出版商:S. Karger GmbH
年代:1990
数据来源: Karger
|
10. |
Megestrol Acetate in Cachectic Patients with Advanced Bronchogenic Cancer |
|
Onkologie,
Volume 13,
Issue 4,
1990,
Page 285-287
M. Heckmayr,
U. Gatzemeier,
Preview
|
PDF (1204KB)
|
|
摘要:
Megestrol acetate, a semisynthetic gestagen, is effective not only for endocrine therapy of advanced breast carcinoma, but also in treatment of cachectic patients with aggressive, hormone-independent tumors. 40 patients with therapy-resistent, advanced bronchogenic carcinoma of different histologic type, who had lost more than ten percent of their regular body weight within a prospective, non-randomized trial were treated with megestrol acetate at a dose of either 160 mg/day or 480mg/day for 3–4 months. The average weight gain of all patients was 3.0 kg. Nearly all of them (80%) reported improved appetite and well-being. The weight gain in the group of patients receiving 160 mg/ day was higher (80 %) than in the group receiving 480 mg/day (50 %) suggesting that the lower dose is as effective as the higher one for palliative treatmen
ISSN:0378-584X
DOI:10.1159/000216777
出版商:S. Karger GmbH
年代:1990
数据来源: Karger
|
|